Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2011-07-19
2011-07-19
Harris, Alana M (Department: 1643)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S004000, C435S007210, C435S007230, C436S063000, C436S064000, C436S174000
Reexamination Certificate
active
07981618
ABSTRACT:
Patients with ErbB2-overexpressing cancers can be given an ErbB2 targeting agent as a therapeutic regimen but not all patients are responsive. The present invention concerns the diagnostic, prognostic and therapeutic methods and compositions for evaluating potential efficacy of an ErbB2 targeting agent in an ErbB2-overexpressing cancers by evaluating PTEN expression, which is predictive of responsiveness or resistance to ErbB2 targeting agents such as trastuzumab. Low PTEN expression is predictive of a patient who will respond poorly to trastuzumab.
REFERENCES:
patent: 6020199 (2000-02-01), Monia et al.
patent: 2002/0150954 (2002-10-01), Durden
patent: 2003/0059764 (2003-03-01), Ravkin et al.
patent: WO 2006/044748 (2006-04-01), None
patent: WO 2005/044091 (2008-05-01), None
Bacus et al. Differences in response of breast cancer molecular profiles of patients likely to respond either to erbB tyrosine kinase inhibitors or to erbB targeted antibodies, Abstract 314, 82(Suppl. 1): S72-73, Nov. 24, 2003.
Xia et al. Lapatinib Antitumor Activity is no dependent upon Phosphatase and Tensin Homologue Deleted on Chromosome 10 in ErbB2-Overexpression Breast Cancers, Cancer Research 67(3): 1170-1175, Feb. 1, 2007.
Crowder et al. (Cancer Cell: 6: 103 and 104, Aug. 2004).
Meric-Bernstam and Hung. Advances in Targeting Human Epidermal Growth Factor Receptor-2 Signaling for Cancer Therapy. Clin. Cancer Res. 12(21): 6326-6330.
Normanno et al. Target-based agents against ErbB receptores and their ligands: a novel approach to cancer treatment. Endocrine-Related Cancer 10: 1-21, 2003.
Eng, Charis. PTEN: One Gene, Many Syndromes. Human Mutation 22: 183-198, Sep. 2003.
Oesterreich et al. Tumor suppressor genes in breast cancer. Endocrine-Related Cancer 6: 405-419, 1999.
Depowski et al. Loss of Expression of the PTEN gene protein product is associated with poor outcome in breast cancer. Mod. Pathol. 14(7): 672-676, 2001.
Bael, Timothy E. Predictive value of Her-2/Neu over-expression and PTEN deletion in high-risk primary breast cancer patients treated with high-dose chemotherapy and stem-cell support. 2ndYear Research Elective Resident's Journal. V: 8-13, 2000-2001.
Albanell and Baselga, “Unraveling resistance to trastuzumab (Herceptin): insulin-like growth factor-I receptor, a new suspect,”J. Natl. Cancer Inst., 93(24):1830-1832, 2001.
Bange et al., “Molecular targets for breast cancer therapy and prevention,”Nat. Med., 7(5):548-552, 2001.
Baselga et al., “Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2
eu-overexpressing metastatic breast cancer,”J. Clin., Oncol., 14(3):737-744, 1996.
Belsches-Jablonski et al., “Src family kinases and HER2 interactions in human breast cancer cell growth and survival,”Oncogene, 20:1465-1475, 2001.
Cantley and Neel, “New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway,”Proc. Natl. Acad. Sci. USA, 96(8):4240-4245, 1999.
Cobleigh et al., “Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease,”J. Clin., Oncol., 17(9):2639-2648, 1999.
Corner and Parent, “PI 3-kinases and PTEN: how opposites chemoattract,”Cell, 109(5):541-544, 2002.
Depowski et al.,“Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer,”Mod. Pathol., 14(7):672-676, 2001.
Di Cristofano and Pandolfi, “The multiple roles of PTEN in tumor suppression,”Cell, 100(4):387-390, 2000.
Drebin et al., “Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies,”Cell, 41(3):pp. 695-706, 1985.
GenBank Accession No. AAC51183, Apr. 1, 1997.
GenBank Accession No. U93051, Apr. 1, 1997.
Georgescu et al., “The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region,”Proc. Natl. Acad. Sci. USA, 96(18):10182-10187, 1999.
Hudziak et al., “p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor,”Mol. Cell Biol., 9(3):1165-1172, 1989.
Ignatoski et al., “ERBB-2 overexpression confers PI 3' kinase-dependent invasion capacity on human mammary epithelial cells,”Br. J. Cancer, 82(3):666-674, 2000.
Iijima and Devreotes, “Tumor suppressor PTEN mediates sensing of chemoattractant gradients,”Cell, 109(5):599-610, 2002.
Jacobs et al., “Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2
eu in breast cancer,”J. Clin. Oncol., 17(7):1974-1982, 1999.
Joki et al., “Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398,”Cancer Res., 60(17):4926-31, 2000.
Koul et al., “Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity,” Oncogene, 21:2357-2364, 2002.
Lee et al., “Expression of small interfering RNAs targeted agaisnt HIV-1 rev transcripts in human cells,”Nature Biotechnology, 19:500-505, 2002.
Leslie and Downes, “PTEN: The down side of PI 3-kinase signalling,”Cell Signal, 14(4):285-295, 2002.
Li and Sun, “PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells,”Proc. Natl. Acad. Sci. USA, 95:15406-15411, 1998.
Li et al., “PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer,”Science, 275:1943-1947, 1997.
Lu et al., “Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades,”J. Biol. Chem., 278:40057-40066, 2003.
Molina et al., “Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells,”Cancer Res., 61(12):4744-4749, 2001.
Mutter et al., “Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers,”J. Natl. Cancer Inst., 92(11):924-930, 2000.
Nagata et al., “PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predictes trastuzumab resistance in patients,”Cancer Cell, 6:117-127,2004.
Palka and Green, “Roles of plakoglobin end domains in desmosome assembly,”J. Cell Sci., 110(pt 19):2359-71, 1997.
Pegram et al., “Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2
eu monoclonal antibody plus cisplatin in patients with HER2
eu-overexpressing metastatic breast cancer refractory to chemotherapy treatment,”J. Clin., Oncol., 16(8):2659-2671, 1998.
Perren et al., “Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast,”Am. J. Pathol., 155(4):1253-1260, 1999.
Petit et al., “Neutralizing antibodies against epidermal growth factor and ErbB-2
eu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors,”Am. J. Pathol., 151(6):1523-1530, 1997.
Sano et al., “Immuno-PCR: very sensitive antigen detection by means of specific antibody-DNA conjugates,”Science, 258(5079):120-2, 1992.
Shepard et al., “Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic,”J. Clin. Immunol., 11:117-127, 1991.
Slamon et al., “Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2,”N. Engl. J. Med., 344(11):783-792, 2001.
Sliwkowsk
Esteva Francisco J.
Nagata Yoichi
Sahin Aysegul A.
Yu Dihua
Zhou Xiaoyan
Board of Regents of the University of Texas System
Harris Alana M
Jackson Benjamin G.
Myriad Genetics IP Department
LandOfFree
Diagnostic and therapeutic methods and compositions... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diagnostic and therapeutic methods and compositions..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diagnostic and therapeutic methods and compositions... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2656386